Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation FD Disclosure

Repros Therapeutics Inc. (NASDAQ:RPRX) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.

Story continues below

On December 12, 2016, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated December 12, 2016


About Repros Therapeutics Inc. (NASDAQ:RPRX)

Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company’s Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.

Repros Therapeutics Inc. (NASDAQ:RPRX) Recent Trading Information

Repros Therapeutics Inc. (NASDAQ:RPRX) closed its last trading session down -0.04 at 1.41 with 216,954 shares trading hands.

An ad to help with our costs